Bio-Rad Labs stock down 4% as Q4 revenue and guidance miss expectations By...

Published on 13 Feb 2025 on Investing.com

Bio-Rad Labs stock down 4% as Q4 revenue and guidance miss expectations

Read the rest of the article

Start tracking your investments with Statfolio

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily...

Zacks · via Yahoo Finance 14 Feb 2025

Despite a decline in net sales, Bio-Rad Laboratories Inc (BIO) achieved gross margin expansion an...

GuruFocus.com · via Yahoo Finance 14 Feb 2025

Bio-Rad Labs stock down 4% as Q4 revenue and guidance miss expectations

Investing.com 13 Feb 2025

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In th...

Insider Monkey · via Yahoo Finance 28 Jan 2025

Bio-Rad Laboratories, Inc. (NYSE:BIO), might not be a large cap stock, but it received a lot of...

Simply Wall St. · via Yahoo Finance 26 Dec 2024

Key Insights Using the 2 Stage Free Cash Flow to Equity, Bio-Rad Laboratories fair value estimate...

Simply Wall St. · via Yahoo Finance 29 Nov 2024

We came across a bullish thesis on Bio-Rad Laboratories, Inc. (BIO) on Substack by Stock Analysis...

Insider Monkey · via Yahoo Finance 24 Nov 2024

The company's net income saw a significant surge to $653 million, largely due to a substantial ga...

Investing.com 31 Oct 2024

Net Sales: $650 million, a 2.8% increase from Q3 2023. Life Science Group Sales: $261 million,...

GuruFocus.com · via Yahoo Finance 31 Oct 2024

We recently compiled a list of the 10 Best Organ Transplant and Diagnosis Stocks To Buy Now. In t...

Insider Monkey · via Yahoo Finance 19 Aug 2024